Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. - Wikidata - awgldk - TriplyDB

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

http://www.wikidata.org/entity/Q35602297

about

Clinical validity and utility of genetic risk scores in prostate cancer Polygenic Epidemiology Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling?Truth or Spin? Disease Definition in Cancer Screening.Constructing Hypothetical Risk Data from the Area under the ROC Curve: Modelling Distributions of Polygenic Risk.Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges.Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers.What's new in screening in 2015?Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.Personalised Medicine Approaches to Screening and Prevention.Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality.Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study.Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.Men with a susceptibility to prostate cancer and the role of genetic based screening.Polygenic risk score of shorter telomere length and risk of depression and anxiety in women Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model

P2860

Q26746219-EF15008A-1BEB-4FA3-A6BD-7D354164730A Q26750522-4B59EE42-54A4-4AC9-9FA7-6FE16882F3B1 Q28084601-616BB273-682D-42A9-910A-0867112343CA Q30401159-5CB9070F-011E-4DE2-8B96-3ECD742CB983 Q31064480-18F2456C-66ED-47E6-A29F-6372D573567F Q36229139-8FDB95F9-4356-4628-885C-EC4D37E5DDCA Q36295073-0786BCFC-43B4-4AA6-9E6D-7DA437995730 Q36356727-70F4F76F-5A91-4534-AFB1-B5400A80A198 Q36763159-6EE383B4-1351-4F95-9AA4-F69C18393B60 Q37113165-FEBE565E-6EF3-4A63-BB3E-D96F7D9F97C3 Q37513339-63E1E751-2161-46CD-8DD2-616137FA58C9 Q37578078-4826D1D5-C137-4062-9D1B-E636E2AC3073 Q38871819-57D84C66-A109-4CEB-9A97-6322EE37FADC Q40137394-D2923CDC-640C-48D8-8085-E4389304EACB Q40197199-92DAD892-E39F-4CB6-A2B8-67E5DE64D8D3 Q40208005-842C4588-3A68-40E1-8C2B-E5046DD9B137 Q46777345-89498B0B-B940-401D-AC93-A375AB07C805 Q47171954-D5E8AFEF-1793-4469-81A2-3D3D0939D94B Q47561710-71660DF2-057A-4344-A259-72761546BFB4 Q53423427-38D27867-F5D8-4D7B-936D-AC7422E1317F Q57172887-CE3A01C8-CA32-4DC2-936E-E27A11736F16 Q57177092-A5E01E49-0572-4A90-B0A4-60D19B9A82B8

P2860

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

http://www.wikidata.org/entity/Q35602297

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@ast

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@en

type

label

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@ast

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@en

prefLabel

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@ast

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@en

P1433

Q35602297-EF7CB9D3-3055-430B-A875-551C5E96770C

P1476

Q35602297-0530D310-48C4-4C52-B8E0-84ED9059F002

P2093

Q35602297-00BDBB14-BE33-45C6-A417-9B3B7FE13B1B

Q35602297-0A7AFA2A-4DD3-4757-AC3F-A40E4E69EF54

Q35602297-736D006C-89C4-4EC3-8E94-9217FFCA991D

Q35602297-7536063D-F28D-4394-A9E6-2CC048AAD0D2

Q35602297-B7F1C82D-D9B1-4222-8109-E457DD7CDD82

Q35602297-C713C35D-C458-49F7-8F9E-D930C2B694D7

Q35602297-E11FF6E2-EFBC-45EB-BF48-A6F0C4B6173D

P2860

Q35602297-0D195333-95C6-41BE-834A-D30300AC2260

Q35602297-11CDBD0E-1A7F-4800-92A6-9823DA171030

Q35602297-2A12574F-80E5-4211-A0BC-52CC0F74875A

Q35602297-3BF5AC1E-AFFF-48A3-96A2-FF1048D7B15D

Q35602297-5567FF3E-6635-4225-B3FD-BAE155658854

Q35602297-6C1523C7-2533-4E8C-B04D-F7661F82C0B7

Q35602297-9DAFBBAD-15F2-48AA-BE0C-1B20F268DF37

Q35602297-A6254021-0E4B-4884-BA98-2A95E1F13698

Q35602297-B10FF0D4-0411-4F18-9B1D-DDA0F804F7C8

Q35602297-BEFE74A9-AE42-437D-8535-4C8E46D5D37D

P2888

Q35602297-685B7FB5-8378-4C35-AD65-FFC46116FD42

P304

Q35602297-829906DE-4A0F-4198-A8CC-ED9AC6EBE115

P31

Q35602297-9877294C-3633-49B0-93FD-41BD82A8559E

P356

Q35602297-F5B490DE-5FDB-4D96-A0D1-6B45019DCF1F

P407

Q35602297-900C7CDF-442E-44F9-B609-D7EEBE5811B1

P433

Q35602297-A9660650-9609-4F36-8993-C1397D0FA184

P478

Q35602297-3C6D7FD5-9D14-4B0B-AE38-CBCBC39ABA13

P50

Q35602297-144F65F4-BCA2-4FA4-820E-0D6976FB1DBA

Q35602297-53648DE5-279A-426F-A7C6-1DA88A6579DE

Q35602297-543F5B08-DC04-408E-AAC5-CF2CA2C5979F

Q35602297-5796BD02-EA0D-4768-9CBE-CE830605654F

Q35602297-91E908D8-DE5F-4FB1-B0C8-765AD40971E3

Q35602297-AA0B268B-21AC-4E53-AA15-16FD32832C48

Q35602297-B9FD172A-E096-4DC5-ACAC-FCA9A371578F

P577

Q35602297-AD5821E7-056E-431E-969B-D6CE54E9ABBC

P5875

Q35602297-F2B67174-F08A-44E2-BD79-EE1A3D225AFF

P698

Q35602297-6EA6BF15-D6C6-4A7D-9B39-C118B5624467

P932

Q35602297-05A8936A-2CA2-453B-A32C-9E3F00A25CFE

P356

P1433

Genetics in Medicine

P1476

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

@en

P2093

Ali Amin Al Olama

http://www.w3.org/2001/XMLSchema#string

Freddie C Hamdy

http://www.w3.org/2001/XMLSchema#string

Jenny L Donovan

http://www.w3.org/2001/XMLSchema#string

Mitul Shah

http://www.w3.org/2001/XMLSchema#string

Patricia Harrington

http://www.w3.org/2001/XMLSchema#string

Richard M Martin

http://www.w3.org/2001/XMLSchema#string

Stephen W Duffy

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays

Association of prostate cancer risk variants with clinicopathologic characteristics of the disease

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.

Personalized screening for cancers: should we consider polygenic profiling?

Risk stratification in prostate cancer screening.

P2888

P304

789-795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GIM.2014.192

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Zsofia Kote-Jarai

Douglas F. Easton

Paul D P Pharoah

P577

2015-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270651314

http://www.w3.org/2001/XMLSchema#string

P698

25569441

http://www.w3.org/2001/XMLSchema#string

P932

4430305

http://www.w3.org/2001/XMLSchema#string